Fusion Pharmaceuticals Inc

Company profile

About

Fusion Pharmaceuticals (NASDAQ:FUSN) is a company focused on the development and commercialization of targeted alpha therapies (TATs) for treating cancer. This innovative approach aims to deliver highly potent alpha-emitting isotopes directly to tumor cells, minimizing damage to surrounding healthy tissue. Their pipeline includes several projects in various stages of development, aiming to address various types of cancers with unmet medical needs. Fusion Pharmaceuticals is committed to advancing its technologies and expanding its portfolio through strategic partnerships, research collaborations, and acquisitions to improve treatment outcomes for cancer patients worldwide.

Snapshot

2014Year founded

117Employees

Hamilton, CanadaHead office

Loading Map...

Global footprint

Operations

All Locations

Hamilton, CA

Products and/or services of Fusion Pharmaceuticals Inc

Targeted alpha therapies (TATs) designed to treat a variety of cancers by delivering alpha particle emitting isotopes directly to tumor cells.
FPI-1434, a product in development for the treatment of tumors expressing IGF-1R, utilizing alpha-emitting isotope Actinium-225.
FPI-1966, aimed at treating FGFR3-expressing tumors, including bladder and other cancers, by utilizing the alpha-emitting isotope Actinium-225.